Identifying better practices for early-stage bladder cancer

Medical Care

Volumn 49, Issue 12, 2011, Pages 1112-1117

  Hollingsworth, John Malcolm ^a,b,c   Zhang, Yun S ^a   Miller, David C ^a,c,d   Skolarus, Ted A ^a,c,d   Wood, David P ^d   Lee, Cheryl T ^d   Montie, James E ^a,c,d   Hollenbeck, Brent K ^a,c,d  

^a Dow Division of Health Services Research   (United States)

^b Department of Urology   (United States)

^c Center for Health Outcomes and Policy   (United States)

^d UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

physician practice patterns; SEER program; urinary bladder neoplasms therapy

Indexed keywords

AGED; ARTICLE; BLADDER CANCER; CLINICAL PRACTICE; COHORT ANALYSIS; CYSTOSCOPY; DISEASE SEVERITY; FEMALE; HEALTH CARE UTILIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; NORMAL HUMAN; PRACTICE GUIDELINE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RISK ASSESSMENT; URINE CYTOLOGY; UROLOGY;

ADMINISTRATION, INTRAVESICAL; AGED; AGED, 80 AND OVER; CYSTOSCOPY; FEMALE; HEALTH SERVICES RESEARCH; HUMANS; MALE; PHYSICIAN'S PRACTICE PATTERNS; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; RISK FACTORS; SEER PROGRAM; SEVERITY OF ILLNESS INDEX; URINARY BLADDER NEOPLASMS;

EID: 81355127488     PISSN: 00257079     EISSN: 15371948     Source Type: Journal    
DOI: 10.1097/MLR.0b013e3182353baf     Document Type: Article

References (26)

1. Jemal A, Siegel R, Xu J, et al. Cancer statistics, 2010. CA Cancer J Clin. 2010;60:277-300.
2. Schrag D, Hsieh LJ, Rabbani F, et al. Adherence to surveillance among patients with superficial bladder cancer. J Natl Cancer Inst. 2003;95: 588-597. (Pubitemid 36553505)
3. Hollingsworth JM, Zhang Y, Krein SL, et al. Understanding the variation in treatment intensity among patients with early-stage bladder cancer. Cancer. 2010;116:3587-3594.
4. Hollenbeck BK, Ye Z, Dunn RL, et al. Provider treatment intensity and outcomes for patients with early-stage bladder cancer. J Natl Cancer Inst. 2009;101:571-580.
5. Hall MC, Chang SS, Dalbagni G, et al. Guideline for the management of nonmuscle invasive bladder cancer (stages Ta, T1, and Tis): 2007 update. J Urol. 2007;178:2314-2330. (Pubitemid 350080987)
6. Shelley MD, Court JB, Kynaston H, et al. Intravesical bacillus Calmette-Guerin versus mitomycin C for Ta and T1 bladder cancer. Cochrane Database Syst Rev. 2003;CD003231.
7. Sylvester RJ, van der Meijden AP, Lamm DL. Intravesical bacillus Calmette-Guerin reduces the risk of progression in patients with superficial bladder cancer: a meta-analysis of the published results of randomized clinical trials. J Urol. 2002;168:1964-1970.
8. Olsen LH, Genster HG. Prolonging follow-up intervals for non-invasive bladder tumors: a randomized controlled trial. Scand J Urol Nephrol Suppl. 1995;172:33-36.
9. Fisher ES, Welch HG. Avoiding the unintended consequences of growth in medical care: how might more be worse? JAMA. 1999;281:446-453. (Pubitemid 29069443)
10. Radford MJ, Foody JM. How do observational studies expand the evidence base for therapy? JAMA. 2001;286:1228-1230. (Pubitemid 33015553)
11. Stukel TA, Fisher ES, Wennberg DE, et al. Analysis of observational studies in the presence of treatment selection bias: effects of invasive cardiac management on AMI survival using propensity score and instrumental variable methods. JAMA. 2007;297:278-285. (Pubitemid 46143305)
12. Hankey BF, Ries LA, Edwards BK. The Surveillance, Epidemiology, and End Results Program: a national resource. Cancer Epidemiol Biomarkers Prev. 1999;8:1117-1121. (Pubitemid 30004912)
13. Greene FL, Page EL, Flemming ID. AJCC Cancer Staging Manual. (ed 6). New York: Springer-Verley; 2002.
14. Percy C, Van Holton V, Muir CE. International Classification of Diseases for Oncology. (ed 2). Geneva: World Health Organization; 1990.
15. American Medical Association. Current Procedure Terminology, CPT 2005. Standard Edition. Chicago: AMA Press; 2004.
16. Diez Roux AV, Merkin SS, Arnett D, et al. Neighborhood of residence and incidence of coronary heart disease. New Engl J Med. 2001;345: 99-106. (Pubitemid 32634569)
17. Klabunde CN, Potosky AL, Legler JM, et al. Development of a comorbidity index using physician claims data. J Clin Epidemiol. 2000;53:1258-1267. (Pubitemid 32007842)
18. Klabunde CN, Harlan LC, Warren JL. Data sources for measuring comorbidity: a comparison of hospital records and Medicare claims for cancer patients. Med Care. 2006;44:921-928. (Pubitemid 44454569)
19. US Public Health Service. International Classification of Diseases, 9th Revision (PHS) 92-1260. Washington: US GPO; 1992.
20. Rabe-Hesketh S, Skrondal A. Multilevel and Longitudinal Modeling Using Stata. (ed 2). College Station: Stata Press; 2008.
21. Gibbons RD, Hur K, Bhaumik DK, et al. Profiling of county-level foster care placements using random-effects Poisson regression models. Health Serv Outcomes Res Method. 2007;7:97-108. (Pubitemid 350064629)
22. Cox DR, Oakes D. Analysis of Survival Data. London: Chapman and Hall; 2001.
23. White H. A heteroskedasticity-consistent covariance matrix estimator and a direct test for heteroskedasticity. Econometrica. 1980;48:817-830.
24. Landman J, Chang Y, Kavaler E, et al. Sensitivity and specificity of NMP-22, telomerase, and BTA in the detection of human bladder cancer. Urology. 1998;52:398-402. (Pubitemid 28399904)
25. Deyo RA. Cascade effects of medical technology. Annu Rev Public Health. 2002;23:23-44. (Pubitemid 34508065)
26. Surveillance, Epidemiology, and End Results (SEER) Program. Available at: http://www.seer.cancer.gov/. Accessed, 2011.